Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein(Oncotherapeutics (United States)), Robert Pordy(Inserm), Robert Dufour(Myovant Sciences (United States)), Daniel Gaudet(Brigham and Women's Hospital), Robert Weiss(Maine Research Associates), Dan Gipe(Regeneron (United States)), Richard Wu(Regeneron (United States)), Jean Bergeron(Université du Québec à Chicoutimi)
Cited by 579
Related Papers
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
|Nature Genetics|2000|1.8k
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
|New England Journal of Medicine|2015|1.5k
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
|New England Journal of Medicine|2008|1.2k
Hypertriglyceridemic Waist
|Circulation|2000|934